Determining the clinical efficacy and predictive biomarkers of mirvetuximab soravtansine (IMGN853) in folate receptor alpha (FRA) expressing, chemotherapy refractory triple negative breast cance

Administered By

Contributors

Start/End

  • December 1, 2016 - March 5, 2019